Labcorp completes acquisition of toxikon corporation

Burlington, n.c.--(business wire)--labcorp (nyse: lh), a leading global life sciences company, today announced that it has closed its acquisition of toxikon corporation, a contract research organization delivering best-in-class nonclinical testing services. the addition of toxikon to labcorp drug development bolsters labcorp's strong nonclinical development portfolio, and creates a strategic footprint for the company to partner with pharmaceutical and biotechnology clients in the boston, mass.,
LH Ratings Summary
LH Quant Ranking